好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Gastric Retention of the Accordion Pill™: Results From MRI Studies With Parkinson’s Disease Patients and Healthy Volunteers
Movement Disorders
P2 - Poster Session 2 (5:30 PM-6:30 PM)
10-050
 To determine gastric retention (GR) of the Accordion Pill™ (AP) in patients with Parkinson’s disease (PD) and healthy volunteers.
While carbidopa/levodopa (CD/LD) is the gold standard treatment for PD, patients experience progressive motor fluctuations with ongoing treatment. Retaining the dosage form that contains LD in the stomach and gradually releasing the drug, may facilitate prolonged absorption, improving efficacy and safety while reducing daily dosing. AP-CD/LD is a novel drug delivery system based on GR of multilayer films containing immediate-release CD and both immediate- and controlled-release LD.
In an open label, randomized, 3-way crossover study (IN-08-004), patients with PD (18–75 y) received AP following their regular morning PD treatment. Three mechanically unique APs (weak, semi-weak, strong) were administered on test days with ≥48 h washout; meals were standardized. Magnetic resonance imaging (MRI) was conducted post-dose at 3, 5, 7, 9, 11, and 13 hours. In a second open label study, healthy volunteers received AP following overnight fasting; sequential MRIs were conducted every 1 h for 11 h, with breakfast and lunch standardized. Safety was assessed via adverse events (AEs).  

Of 18 patients enrolled, 83.3% were male and mean (SD) PD duration was 8.9 (4.6) y. Mean GR was 11.8 (7.3), 13.5 (5.8), and 13.9 (6.5) h for weak, semi-weak, and strong AP. In 11 healthy volunteers, the AP remained in the stomach for 8, 9, and 11 h in 100%, 91%, and 73% of participants. One serious AE (IN-08-004: general weakness/worsening of PD) was reported. Mild AEs of headache, nausea, and vomiting were reported in one participant and pain during MRI in another; all resolved.

AP GR was approximately 12 h in PD patients and 8 to 11 h in healthy volunteers. AP-CD/LD, currently in phase 3 development for PD, may improve efficacy and safety of LD treatment.

Authors/Disclosures

PRESENTER 		No disclosure on file
R. Michael Gendreau No disclosure on file